LONDON, Nov 16 (Reuters) - GlaxoSmithKline Plc’s (GSK.L: Quote, Profile, Research) new breast cancer pill Tykerb will receive a priority review from U.S. regulators in a move that should speed its path onto the world’s biggest drugs market next year, it said on Thursday.
